OBJECTIVE: Telestroke systems are tools, used to provide an advanced stroke care in regions without sufficient neurologic services. We performed this meta-analysis to assess the effects of telemedicine on treatment times and clinical outcomes of acute stroke care. METHODS: A literature search of PubMed, SCOPUS, and Cochrane CENTRAL was conducted for original studies investigating telemedicine applications in acute stroke care. Dichotomous data on treatment outcomes were pooled as odds ratios (ORs), while continuous data on thrombolysis times were pooled as mean differences (MDs) with 95% confidence interval (CI), using RevMan software (version 5.3). RESULTS: Pooling data from 26 studies (6605 thrombolysed patients) showed no significant differences between the telestroke and control groups in terms of in-hospital mortality (OR = 1.21, 95% CI [0.98, 1.49]), 90-day mortality (OR = 1.08, 95% CI [0.85, 1.37]), symptomatic intracranial hemorrhage (sICH) (OR = 1.10, 95% CI [0.79, 1.53]), and favorable clinical outcome at discharge (OR = 1.03, 95% CI [0.69, 1.53]) and 90 days later (OR = 0.99, 95% CI [0.82, 1.18]). The onset-to-door (OTD) duration (MD = -10.4 minutes, 95% CI [-14.79, -.01]) and length of hospital stay (MD = -0.55 days, 95% CI [-1.02, -0.07]) were significantly shorter in the telestroke group, compared to the control group. Although the overall effect estimate (under the fixed-effect model) showed a significant decrease in the onset-to-treatment (OTT) duration in the telestroke group (MD = -5.83 minutes, 95% CI [-8.57, -3.09]), employing the random-effects model for between-study heterogeneity abolished this significance (MD = -5.90 minutes, 95% CI [-13.23, 1.42]). CONCLUSION: Telestroke significantly reduced OTD and hospital stay durations in stroke patients without increasing the risk of mortality or sICH. Therefore, telemedicine can improve stroke care in regional areas with minor experience in thrombolysis. Further randomized controlled trials are needed to assess the benefits of telestroke systems, especially in terms of cost-effectiveness and quality of life outcomes.
OBJECTIVE:Telestroke systems are tools, used to provide an advanced stroke care in regions without sufficient neurologic services. We performed this meta-analysis to assess the effects of telemedicine on treatment times and clinical outcomes of acute stroke care. METHODS: A literature search of PubMed, SCOPUS, and Cochrane CENTRAL was conducted for original studies investigating telemedicine applications in acute stroke care. Dichotomous data on treatment outcomes were pooled as odds ratios (ORs), while continuous data on thrombolysis times were pooled as mean differences (MDs) with 95% confidence interval (CI), using RevMan software (version 5.3). RESULTS: Pooling data from 26 studies (6605 thrombolysed patients) showed no significant differences between the telestroke and control groups in terms of in-hospital mortality (OR = 1.21, 95% CI [0.98, 1.49]), 90-day mortality (OR = 1.08, 95% CI [0.85, 1.37]), symptomatic intracranial hemorrhage (sICH) (OR = 1.10, 95% CI [0.79, 1.53]), and favorable clinical outcome at discharge (OR = 1.03, 95% CI [0.69, 1.53]) and 90 days later (OR = 0.99, 95% CI [0.82, 1.18]). The onset-to-door (OTD) duration (MD = -10.4 minutes, 95% CI [-14.79, -.01]) and length of hospital stay (MD = -0.55 days, 95% CI [-1.02, -0.07]) were significantly shorter in the telestroke group, compared to the control group. Although the overall effect estimate (under the fixed-effect model) showed a significant decrease in the onset-to-treatment (OTT) duration in the telestroke group (MD = -5.83 minutes, 95% CI [-8.57, -3.09]), employing the random-effects model for between-study heterogeneity abolished this significance (MD = -5.90 minutes, 95% CI [-13.23, 1.42]). CONCLUSION: Telestroke significantly reduced OTD and hospital stay durations in strokepatients without increasing the risk of mortality or sICH. Therefore, telemedicine can improve stroke care in regional areas with minor experience in thrombolysis. Further randomized controlled trials are needed to assess the benefits of telestroke systems, especially in terms of cost-effectiveness and quality of life outcomes.
Authors: Richa Sharma; Kori S Zachrison; Anand Viswanathan; Marcelo Matiello; Juan Estrada; Christopher D Anderson; Mark Etherton; Scott Silverman; Natalia S Rost; Steven K Feske; Lee H Schwamm Journal: Circ Cardiovasc Qual Outcomes Date: 2020-03-04
Authors: Amir Alishahi Tabriz; Kea Turner; Dunc Williams; Nimmy Babu; Steve North; Christopher M Shea Journal: Telemed J E Health Date: 2021-09-24 Impact factor: 5.033
Authors: Annie N Simpson; Jillian B Harvey; Steven M DiLembo; Ellen Debenham; Christine A Holmstedt; Cory O Robinson; Kit N Simpson; Eyad Almallouhi; Dee W Ford Journal: Telemed J E Health Date: 2020-02-11 Impact factor: 3.536
Authors: Oliver T Nguyen; Amir Alishahi Tabriz; Jinhai Huo; Karim Hanna; Christopher M Shea; Kea Turner Journal: J Med Internet Res Date: 2021-05-05 Impact factor: 5.428
Authors: Carlos Fernandez-Lozano; Pablo Hervella; Virginia Mato-Abad; Manuel Rodríguez-Yáñez; Sonia Suárez-Garaboa; Iria López-Dequidt; Ana Estany-Gestal; Tomás Sobrino; Francisco Campos; José Castillo; Santiago Rodríguez-Yáñez; Ramón Iglesias-Rey Journal: Sci Rep Date: 2021-05-12 Impact factor: 4.379
Authors: Morgan B Swanson; Aspen C Miller; Marcia M Ward; Fred Ullrich; Kimberly As Merchant; Nicholas M Mohr Journal: J Telemed Telecare Date: 2019-11-04 Impact factor: 6.344
Authors: Michael Lyerly; Griffin Selch; Holly Martin; Michelle LaPradd; Susan Ofner; Glenn Graham; Jane Anderson; Sharyl Martini; Linda S Williams Journal: Stroke Date: 2020-11-23 Impact factor: 7.914
Authors: Nicholas M Mohr; Kalyn D Campbell; Morgan B Swanson; Fred Ullrich; Kimberly A Merchant; Marcia M Ward Journal: J Telemed Telecare Date: 2020-01-05 Impact factor: 6.344
Authors: Emilio Rodríguez-Castro; Iria López-Dequit; María Santamaría-Cadavid; Susana Arias-Rivas; Manuel Rodríguez-Yáñez; José Manuel Pumar; Pablo Hervella; Esteban López-Arias; Andrés da Silva-Candal; Ana Estany; María Piñeiro-Lamas; Tomás Sobrino; Francisco Campos; Manuel Portela; Manuel Vázquez-Lima; José Castillo; Ramón Iglesias-Rey Journal: BMC Neurol Date: 2018-10-03 Impact factor: 2.474